The people want peptides.
Qual time. Listen Ventures conducted in-depth interviews with 27 consumers on self-directed peptide use, finding:
- GLP-1s were a psychological gateway, normalizing self-injections.
- Most discovered peptides through social proof, not doctor’s orders.
- Top sources were medspas, online vendors, and compounding pharmacies.
An $80B global market, peptides have spread via group chats, gym crews, celebs, and influencers, with users considering them a more natural, low-risk alternative to steroids and invasive anti-aging procedures.
Interestingly, they don’t see peptides as a shortcut so much as an accelerant — speeding recovery so they can train more and maximize ROI of already dialed health routines.
Stalemate. Traditional physicians and peptide takers are mutually dismissive of each other, leading the latter to turn to chiros, medspas, health coaches, PTs, and functional docs. But with legalities limiting guidance, early adopters are largely self-governed.
To grow beyond fringe enthusiasts, the category will need infrastructure for second-wave consumers, addressing counterfeit risks, mislabeling, and contamination.
Evolving in real time, RFK Jr. said on Joe Rogan that HHS wants to revisit how certain peptides are classified, potentially opening the door to broader access through licensed channels.
Meanwhile, retatrutide—Eli Lilly’s next-gen GLP-1—is undergoing Phase III clinical trials, forcing a reckoning between backchannels and Big Pharma.
Baby steps. Tracking gray-market activity, Finnrick Analytics tests and rates peptide supply chains to “make sovereign health safer.” After a SuppCo user survey showed demand from 90% of respondents, the company said it’s launching in-app peptide tracking in March.
Looking ahead: Some experts warn peptides aren’t proven, but optimizers are running their own experiments. With consumers buying in, a new market is taking shape.
